Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of ...

The first engineered cell therapy has come to the fight against solid tumors. Fox Chase Cancer Center has begun using Tecelra, an FDA-approved treatment for synovial sarcoma.

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...

Northwestern Medicine scientists have identified the cellular mechanisms that cause immune cells to differentiate and ultimately lose function during viral infection, findings that could improve ...

An integrin mutation impairs skin T cell migration, enabling HPV proliferation that causes warts and lesions in a rare genetic dermatological condition.

As interest in CAR T cells and immune-based oncology therapies increases, efficient phenotyping of cell therapy products ...